RxDoctor Payments Data

Ace Anglin, DPM

Podiatrist · Montgomery, ALNPI 1639165434

Payments from drug & device makers

What this record shows

This record is dominated by education: $537 of the $744 with a category attached, or 72.2%. 7 manufacturers reported payments, led by Rikco International, LLC at 57.1% of the total. Reporting peaked in 2019 at $465 and has fallen 56.6% since, to $202 in 2025. That places this record below the midpoint for podiatrist clinicians in AL, where the typical reported total is $1,120.

$744in general payments, 2019–2025

Across 16 payments — averaging $46.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rikco International, LLC$425
  • DJO, LLC$112
  • Paratek Pharmaceuticals, Inc.$89
  • Smith+Nephew$61
  • IBSA Pharma Inc.$21
  • Averitas Pharma Inc.$20
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$20728%
  • Education$53772%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Rikco International, LLC4$425
DJO, LLC2$112
Paratek Pharmaceuticals, Inc.4$89
Smith+Nephew3$61
IBSA Pharma Inc.1$21
Averitas Pharma Inc.1$20
Alfasigma USA, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$744 in reported general payments places this provider in the 40th percentile of 59 podiatrist providers in Alabama.

See all podiatrist providers in Alabama

Medicare billing

Part B allowed, 2024
$73,186
Medicare patients
200
Services billed
940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox837$35,524
Ammonium Lactate977$29,357
Clotrimazole733$8,221
SantylCollagenase Clostridium Hist.14$4,845
Diclofenac Sodium49$1,513
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav64$1,056
Nystatin55$746
Triamcinolone Acetonide55$371
Terbinafine Hcl17$345
Methylprednisolone31$299
SsdSilver Sulfadiazine15$160
Levofloxacin11$76
Meloxicam25$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$61$4,84514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 59 podiatrist providers in Alabama.

Other podiatrist in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →